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ABSTRACT
A new procedure which combines LASIK and
corneal cross-linking (Lasik Xtra) has been
proposed as an alternative to traditional
LASIK. It is aimed at restoring strength to the
cornea, increasing stability in visual outcomes,
increasing the accuracy of the refractive
correction, and potentially lowering
enhancement rates. This article reviews the
current clinical evidence which has been
published on the topic and reviews both the
safety and efficacy argument for the procedure.
Keywords: Laser in situ keratomileusis; LASIK;
Riboflavin; UVA mediated corneal cross-linking
INTRODUCTION
Laser in situ keratomileusis (LASIK) is the most
commonlyperformed refractive procedure in the
United States, due inpart to rapidvisual recovery,
minimal postoperative discomfort, and
perceived improvement in patient quality of
life [1]. However, despite advancements in
femtosecond and excimer laser technology, and
the adoption of more thorough diagnostic
screening approaches, the procedure is not
without impact on the biomechanical
properties of the cornea. LASIK requires the
creation of a flap and the removal of tissue,
which may result in weakening of the anterior
corneal stroma and decreasing overall corneal
rigidity [2, 3]. This may be one mechanism that
contributes to regression of refractive effect
leading to ‘‘enhancement’’ (retreatment)
procedures [4]. In rare cases, weakening can
result in corneal ectasia and associated
progressive degradation of vision [5]. As the
effects of corneal weakening become better
understood, effort is being applied to reduce
impact on treatmentoutcomes.Averypromising
approach for restoration of corneal stability in
these instances is riboflavin/ultraviolet A
(UVA)-mediated corneal cross-linking (CXL).
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CXL was first introduced in the late 1990s in
Dresden, Germany as a means of stabilizing the
cornea, and the procedure has been rapidly
adopted outside of the United States as a
standard therapy for treatment of keratoconus
(KC) and iatrogenic corneal ectasia [6]. The
conventional CXL treatment approach for KC
and ectasia has been shown to not only stabilize
the cornea, but to result in corneal flattening,
on the order of more than 1 D [7]. Many of the
mechanisms and controls underlying CXL have
been studied and predictive chemical [8] and
biomechanical methods [9, 10] have been
developed to better understand CXL. Details of
the mechanisms underlying CXL are an area of
fertile research, beyond the scope of this paper.
While the initial cross-linking technique
utilized a low irradiance (3 mW/cm2) UVA
source requiring 30 min of irradiation time,
accelerated cross-linking techniques, first
proposed 7 years ago [11], have more recently
been introduced clinically to dramatically
shorten procedure time [12]. Accelerated
cross-linking using higher irradiance (30 mW/
cm2) has been demonstrated to be effective at
stabilizing and reducing corneal curvature in
patients with keratoconus or iatrogenic corneal
ectasia. Studies have shown that its effects are
equivalent to conventional CXL in terms of
efficacy at stabilizing the cornea, with an
equivalent or better safety profile [13–15].
LASIK in combination with CXL (Lasik Xtra
Avedro, Massachusetts, USA) is an alternative to
traditionalLASIKaimedat restoring strength to the
cornea, increasing stability in visual outcomes,
increasing theaccuracyof the refractivecorrection,
and potentially lowering enhancement rates.
Corneal cross-linking has been shown to enhance
the structural integrity of the cornea, in both
animal studies [16] and in clinical practice,
stiffening the cornea [17] and halting the
progression of ectasia such as keratoconus [18]. It
is logical to anticipate that stiffening a cornea,
which has been structurally weakened by LASIK,
through the addition of CXL, may minimize the
negativeeffects associatedwith thisbiomechanical
compromise. In other words, the aim of Lasik Xtra
is to further reduce the rare incidence of iatrogenic
ectasia, as well as to reduce the rate of treatment
regression and enhancements.
Although not yet approved in the United
States, LasikXtra is in clinical use inmore than50
countriesworldwide. Theprocedure is frequently
performed on patients who are considered good
candidates for the LASIK procedure, but may fall
into categories associated with greater risk of
post-LASIK regression: those with hyperopia [19]
high amounts of myopia [20], younger patients
and those with borderline-predicted residual
stromal bed thickness [21].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
THE LASIK XTRA PROCEDURE
The Lasik Xtra procedure is performed as follows:
the creation of the LASIK flap and the excimer
ablation are performed in the usual manner;
however, many surgeons adjust their treatment
algorithm toaccount for reductionor elimination
of regression, typically seen in LASIK and
photorefractive keratectomy procedures. Lasik
Xtra is performed immediately following the
excimer ablation. Because the LASIK flap no
longer contributes to the biomechanical
strength of the cornea, the region of stroma
targeted for CXL is the area directly beneath the
ablation zone. At the completion of the excimer
ablation, eyes receive 1–5 drops of Dextran-free
riboflavin formulation (VibeXTM Xtra Avedro,
Massachusetts, USA), carefully applied to the
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stromal bed (avoiding application to the LASIK
flap). The riboflavin solution is allowed to soak for
a period of up to 90 s after which the riboflavin is
rinsed from the stroma using balanced salt
solution. Once well rinsed, the LASIK flap is
repositioned into place and the flap interface
copiously irrigated and stroked into place. A
375 nm UV source with a homogenous 30mW/
cm2 top hat beam profile (KXL, Avedro, MA,
USA) is then used to apply a 2.7 J/cm2 dose of
irradiation through the closed flap [22].
When used in conjunction with LASIK (Lasik
Xtra), the goal of CXL is to restore corneal
strength without creating an additional change
in refraction beyond that provided by the LASIK
correction. Traditional CXL, when applied to
the ectatic cornea, is known to cause a
flattening of the cornea of several diopters;
therefore, it is important to consider the
differences between Lasik Xtra and
conventional CXL.
The soak and irradiance times described
above differ significantly from the
conventional CXL treatment protocol for KC
and ectasia [23], with shorter total riboflavin
soaking times and lesser total UVA dose. The
direct application of riboflavin to the stroma
afforded by the lifted LASIK flap reduces the
required time for sufficient riboflavin to diffuse
into the targeted area of the corneal stroma.
Similarly, while cross-linking for treatment of
ectasia is intended to stiffen a pathologically
weak cornea, it is plausible that less
cross-linking may be required to return an
otherwise healthy cornea to its native strength
subsequent to LASIK.
Theoretical modeling using finite element
analysis by Dupps et al. at The Cleveland Clinic
has demonstrated that focal weaknesses of the
cornea result in the progressive topographic
abnormalities observed in keratoconus, and
that CXL results in dramatic flattening of
corneal curvature [24]. This finite element
analysis model was applied by the same group
to evaluate the impact of Lasik Xtra on response
to deformation in the residual stromal bed
when intra-ocular pressure in doubled, and the
effect on refractive outcome. A myopic LASIK
procedure with a -4.25 D spherical correction
was simulated using a wavefront optimized
ablation profile with an optical zone diameter
of 6.5 mm and overall treatment diameter of
9 mm. The response to deformation and
refractive correction was evaluated with and
without the addition of simulated CXL,
modeled as an increase in stiffness of the
central 9 mm of the stromal bed with an
effective depth of 200 l and a stiffening factor
of 1.59. The addition of CXL resulted in less
displacement when IOP was increased (ie,
cornea is stiffer), however, simulations
demonstrated refractive equivalence between
the cross-linked and uncross-linked eyes [25].
This modeling demonstrated a theoretical basis
for increasing the corneal stiffness without
changing refractive outcome.
CLINICAL OUTCOMES
A number of clinical studies have been
performed to evaluate the performance of
Lasik Xtra using a variety of treatment
methods, examining changes in tissue
morphology, refractive stability and treatment
safety. These studies are summarized in Table 1.
Tissue Morphology
In a case report using laser scanning in vivo
confocal microscopy to evaluate a patient
treated with Lasik Xtra, Mazzotta et al. [26]
observed morphological changes including
hyper-reflectivity and keratocyte apoptosis,
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which are consistent with conventional corneal
cross-linking. The stromal depth of these
features was 150–160 lm, shallower than
conventional CXL. This was for a treatment
using VibeX Xtra, soaking on the stromal bed
for 90 s, and illuminated at 30 mW/cm2 for a
total dose of 2.7 J/cm2. Keratocyte repopulation
occurred by 6 months postoperatively, and no
endothelial damage was observed. These
preliminary findings suggest, as expected,
microstructural changes which occur in Lasik
Xtra and are similar to those found with
conventional cross-linking.
Increased Stability in Visual Outcomes
International studies have shown the benefits of
Lasik Xtra for patients with high myopic and
high hyperopic corrections.
Kanellopoulos [27] reported 2-year follow-up
on a cohort of 34 consecutive patients treated
using Lasik Xtra in conjunction with bilateral,
topography-guided Hyperopic LASIK treatment.
Hyperopic LASIK is well understood to be
subject to significant regression of LASIK
treatment effect. In this study, patients
received LASIK ? CXL in one eye (CXL group)
and LASIK without CXL in the contralateral eye
(no CXL group). In the CXL group, a single drop
of riboflavin solution was placed under the flap
after excimer ablation. The flap was
repositioned, and the CXL eye was irradiated
through the closed flap with 10 mW/cm2 UVA
light for 3 min (KXL). Follow-up evaluations
included refraction, keratometry, topography
and tomography. At baseline, mean spherical
equivalent refractive error (MRSE), cylinder, and
uncorrected distance visual acuity (UDVA)
(decimal) were equivalent in the CXL and no
CXL groups, with MRSE ?3.15 ± 1.46 D,
cylinder 1.20 ± 1.18 D, and UDVA of
0.1 ± 0.26 in the CXL group and MRSE
?3.40 ± 1.78 D, cylinder 1.40 ± 1.80 D and
UDVA of 0.1 ± 0.25 in the no CXL group.
Mean MRSE at 2 years postoperatively was
-0.20 ± 0.56 D and ?0.20 ± 0.40 D in the
CXL and no CXL groups, respectively. Mean
UDVA was 0.95 ± 0.15 (CXL group) and
0.85 ± 0.23 (no CXL group). Greater refractive
regression was observed in the no CXL group
(?0.72 ± 0.19 D) vs. the CXL group
(?0.22 ± 0.31 D) (p = 0.0001).
The same group evaluated the effect of Lasik
Xtra on epithelial thickness profiles in myopic
patients [28]. One hundred thirty-nine
consecutive eyes undergoing LASIK for myopic
correction were enrolled in this prospective
study. Mean baseline refractive error was
-6.58 ± 2.31 D sphere, with cylinder
-1.39 ± 1.4. Eyes were treated with
LASIK ? CXL (Lasik Xtra group, n = 67) or
standalone LASIK (LASIK-only group, n = 72).
Riboflavin solution was applied to the stromal
bed in the Lasik Xtra group immediately after
completion of the excimer ablation. Riboflavin
was soaked for 60 s and then rinsed from the eye
prior to repositioning of the flap. The Lasik Xtra
eyes were then irradiated with 30 mW/cm2 UVA
for 80 s (KXL). LASIK-only eyes did not receive
CXL. Eyes in each treatment group were divided
into subgroups for evaluation by intended
refractive correction. In the high myopia
subgroups, statistically significant differences
in the mid-peripheral epithelial thickness
profile were observed between the Lasik Xtra
and LASIK-only group. In the ‘‘-7.00 to
-8.00 D’’ subgroup, mid-peripheral epithelial
thickness increased by 3.95 lm in the Lasik
Xtra treatment group vs. 7.14 lm in the
LASIK-only group (p = 0.041). In the ‘‘-8.00 to
-9.00 D’’ subgroup, mid-peripheral epithelial
thickness increased by 3.79 lm in the Lasik
Xtra group vs. 9.32 lm in the LASIK-only group
(p = 0.032). No statistically significant
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differences were observed in the subgroups with
lower myopia. The authors proposed that the
greater epithelial hyperplasia observed in the
highly myopic LASIK-only groups may be
correlated with greater refractive regression,
and that less hyperplasia may be observed in
the matched Lasik Xtra groups due to greater
stromal biomechanical stability resulting in less
oscillation of the cornea.
Kanellopoulos also reported a 2-year
follow-up of a prospective observational
longitudinal study of 140 consecutive eyes
enrolled for myopic LASIK correction.
Sixty-five eyes in this cohort underwent Lasik
Xtra according to treatment protocol described
in the previous study. After 24 months
follow-up, UDVA was better than 20/20 in a
greater percentage of eyes in the Lasik Xtra
group (93.8%) than in the LASIK-only group
(84.8%) (p = 0.045). Good refractive accuracy
was obtained in both groups, with linear
regression of the scatterplot of attempted vs.
achieved correction revealing a coefficient of
determination (r2) of 0.975 in the LASIK Xtra
group vs. 0.968 in the LASIK-only group.
However, 2-year postoperative mean MRSE
showed greater refractive shift in the
LASIK-only group vs. the Lasik Xtra group
(p = 0.065), supported by a similar difference
in keratometric stability (p = 0.032). [20].
A study by a group in Singapore provides
further support for refractive stability
improvement associated with Lasik Xtra for
high myopia [29]. In this study, 70
consecutive eyes undergoing LASIK for
correction of high myopia (-8.00 to -19.00 D
manifest refractive spherical equivalent) were
prospectively recruited and treated with Lasik
Xtra and compared with a retrospective
consecutive control group of 64 eyes who had
undergone LASIK alone for correction of high
myopia. Immediately following the laser
ablation, while the flap remained in the taco
position, the stromal bed of the Lasik Xtra eyes
was coated with 6–8 drops of dextran-free
isotonic riboflavin-5-phosphate 0.25% solution
in normal saline (VibeX Xtra). After 45 s, the
riboflavin was rinsed from the stromal bed using
balanced salt solution (BSS), and the flap was
carefully repositioned over the stromal bed.
Additional rinsing with BSS was performed
after the flap was replaced. After confirming
that the flap was properly positioned, the KXL
device was used to apply 365 nm UVA light
exposure for 45 s at a power of 30 mW/cm2 for a
total energy dose of 1.35 J/cm2 to the Lasik Xtra
eyes, through the closed flap. At 3 months
follow-up, 61% of LASIK-only eyes achieved
UDVA of 20/25 or better, compared to 98% of
Lasik Xtra eyes (p\0.001). A greater percentage
of eyes were within ±0.50 of the intended
correction in the Lasik Xtra group (88%) than in
the LASIK-only group (65%) at 3 months
(p = 0.005). Linear regression of the scatterplot
of attempted vs. achieved correction reveals a
coefficient of determination of 0.83 in the
LASIK-only group vs. 0.99 in the Lasik Xtra
group. A trend (p = 0.051) towards greater
refractive drift in the LASIK group (-0.13 D)
vs. the Lasik Xtra group (-0.04 D) was observed.
Treatment Safety
CXL treatment for KC and corneal ectasia has
been found to have a low rate of side effects. It is
not surprising that, as Lasik Xtra produces
similar tissue effects to these treatments, and
uses lower doses for treatment effect, the safety
profile is favorable.
In addition to the studies described above, in
which there were no side effects beyond those
typically associated with LASIK treatment,
several papers have looked at the safety of this
prophylactic treatment.
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The earliest study was a pilot fellow-eye case
series in 4 subjects with 12-month follow-up
conducted in Turkey [30]. At the 12-month
follow-up, the Lasik Xtra group had a UDVA
and manifest refraction equal to or better than
those in the LASIK-only group. No eye lost 1 or
more lines of spectacle-corrected distance visual
acuity at the final visit. The endothelial cell loss
in the Lasik Xtra eye was not greater than in the
fellow eye. No side effects were associated with
either procedure.
A Japanese study [31] found Lasik Xtra to be
safe. In this study, 24 bilateral myopic LASIK
patients underwent unilateral accelerated
cross-linking with the KXL system in the
non-dominant eye. After LASIK, riboflavin
0.1% was instilled in the residual stromal bed
for 60 s. After the riboflavin was washed out and
the flap was placed in its original position, UVA
light (30 mW/cm2) was administered for 60 s,
and the Lasik Xtra eyes were compared with the
LASIK-only eyes. As anticipated, increased
hyper-reflectivity and a demarcation line
similar to that seen after cross-linking were
observed in the Lasik Xtra eyes. A demarcation
line (mean depth 200.04 lm ± 27.01, range
178–278 lm) was observed in 23 eyes (95.8%).
The line was well-defined in two eyes (8.3%)
and faint in 21 eyes (87.5%). The study found
no significant differences in corrected and
uncorrected distance visual acuity, manifest
refraction spherical equivalent, endothelial cell
density, or 37 parameters dynamic bidirectional
applanation readings.
Additionally, in another large study of
routinely treated subjects [21], 601 Lasik Xtra
patients showed stable uncorrected distance
visual acuity over 1 year of follow-up. These
patients showed no significant changes in
manifest refraction spherical equivalent and
average K readings during the 1-year follow-up.
Most recently, TLC Laser Eye Centers, in
Toronto, Canada performed a safety and
efficacy analysis on a series of 30 patients (data
on file). In this series, data were gathered on 30
consecutive Lasik Xtra cases, with patients
selected to be at higher risk of regression, i.e.,
those with high myopia (from -8 to -10) or
hyperopia, high astigmatism, or mixed
astigmatism. Data are being gathered on the
long-term efficacy, but the safety profile of the
procedure has been extremely positive, with no
adverse events.
DISCUSSION
CXL has been utilized in clinical practice for
more than 15 years. The procedure has an
exemplary history of safety and efficacy, as
reported in over 100 clinical studies. While
treatment of KC and corneal ectasia are the
mainstays of these publications, applications
include treatment of corneal infections and
ulcerations (keratitis), and, of course treatment
in conjunction with refractive surgery.
As described above, Lasik Xtra extends the
application of CXL. The reduction in treatment
dose, compared to treatment of KC and ectasia
suggests a reduction in risk of treatment-related
side effects. In six studies, evaluating over 600
eyes, no significant side effects have been
associated with treatment.
Lasik Xtra treatment has been shown to
significantly improve post-LASIK refractive
stability, when compared to LASIK alone. This
has been shown for both myopic and hyperopic
refractive treatments, particularly in those with
high diopter corrections who are at greater risk
of refractive drift. And while the number of
treatments and follow-up is not sufficient to
draw definitive conclusions regarding the
ability of Lasik Xtra to reduce the risk of
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corneal ectasia, the treatment profile may
support prophylactic use.
The combination of low-risk profile and
significant improvement in refractive stability
supports Lasik Xtra as a promising adjunct to
LASIK in reducing the likelihood of enhancement
procedures,particularly in thosepatientswithhigh
diopter corrections, and those with hyperopic
corrections. Four studies that included a total of
41,468 eyes have found that LASIK has an average
retreatment rate of 12%. Most of these occur
during the first 2 years after the LASIK procedure
[4, 32–34]. If the refractive results with Lasik Xtra
are trulymore stable, this should logically result in
lower retreatment rates over time.
CONCLUSION
Lasik Xtra is a new, innovative procedure,
aimed at reducing some of the challenges
associated with LASIK (weaker corneas, and
regression of the refraction over time). As the
clinical evidence concerning the procedure
continues to grow, many practices are finding
that Lasik Xtra is a worthwhile addition to their
armamentarium. The clinical benefits of this
new application of cross-linking technology are
welcome by both patients and practitioners
alike and continued careful evaluation of
outcomes is warranted.
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